Gilead Sciences
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The last earnings update was 17 days ago. More info.
Add to Portfolio Compare Print
GILD Share Price and Events
7 Day Returns
1 Year Returns
GILD Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Gilead Sciences (GILD) | -1.2% | -4.4% | -1.6% | -17.4% | -27.3% | -21.6% |
| US Biotechs | 1.1% | 0.7% | 7.4% | -1.2% | 18.3% | 5.3% |
| US Market | 1.4% | 5.6% | 5.7% | 2.3% | 44.2% | 40.9% |
1 Year Return vs Industry and Market
- GILD underperformed the Biotechs industry which returned -1.2% over the past year.
- GILD underperformed the Market in United States of America which returned 2.3% over the past year.
GILD Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Gilead Sciences
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Gilead Sciences.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 23 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 16.1% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 7.3% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.43 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.426 (1 + (1- 21%) (36.73%)) |
1.84 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.84 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.84 * 7.27%) |
16.11% |
Discounted Cash Flow Calculation for NasdaqGS:GILD using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Gilead Sciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (USD, Millions) | 8,776.13 | 9,205.86 | 8,928.67 | 8,995.33 | 9,417.50 |
| Source | Analyst x8 | Analyst x7 | Analyst x6 | Analyst x6 | Analyst x6 |
|
Present Value Discounted (@ 16.11%) |
7,558.77 | 6,829.06 | 5,704.68 | 4,950.06 | 4,463.52 |
| Present value of next 5 years cash flows | $29,506.09 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= $9,417.50 × (1 + 2.73%) ÷ (16.11% – 2.73%) |
$72,332.36 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= $72,332.36 ÷ (1 + 16.11%)5 |
$34,282.64 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= $29,506.09 + $34,282.64 |
$63,788.74 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $63,788.74 / 1,282.00 |
$49.76 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $49.76 |
| Current discount | Discount to share price of
$65.55
= -1 x ($65.55 - $49.76) / $49.76 |
-31.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Gilead Sciences is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Gilead Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Gilead Sciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $4.20 |
| NasdaqGS:GILD Share Price ** | NasdaqGS (2019-02-21) in USD | $65.55 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 34 Publicly-Listed Biotechs Companies | 22.32x |
| United States of America Market PE Ratio | Median Figure of 3,045 Publicly-Listed Companies | 17.39x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Gilead Sciences.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:GILD Share Price ÷ EPS (both in USD) = 65.55 ÷ 4.20 |
15.6x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Gilead Sciences is good value based on earnings compared to the US Biotechs industry average.
- Gilead Sciences is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Gilead Sciences's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 15.6x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 23 Analysts |
6.3%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 27 Publicly-Listed Biotechs Companies | 1.87x |
| United States of America Market PEG Ratio | Median Figure of 2,118 Publicly-Listed Companies | 1.44x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 15.6x ÷ 6.3% |
2.47x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Gilead Sciences is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Gilead Sciences's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $16.80 |
| NasdaqGS:GILD Share Price * | NasdaqGS (2019-02-21) in USD | $65.55 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 404 Publicly-Listed Biotechs Companies | 3.15x |
| United States of America Market PB Ratio | Median Figure of 5,129 Publicly-Listed Companies | 1.87x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:GILD Share Price ÷ Book Value per Share (both in USD) = 65.55 ÷ 16.80 |
3.9x |
* Primary Listing of Gilead Sciences.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Gilead Sciences is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Gilead Sciences's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Gilead Sciences has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
GILD Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Gilead Sciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Gilead Sciences's earnings growth is positive but not above the United States of America market average.
- Gilead Sciences's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:GILD Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 23 Analysts | 6.3% |
| NasdaqGS:GILD Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 23 Analysts | 0.7% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 19.4% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 14.3% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 12.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 23 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 22,693 | 9,324 | 7,842 | 10 |
| 2022-12-31 | 22,645 | 9,223 | 7,370 | 11 |
| 2021-12-31 | 22,590 | 8,876 | 7,551 | 13 |
| 2020-12-31 | 22,508 | 8,832 | 7,239 | 21 |
| 2019-12-31 | 21,948 | 8,647 | 6,542 | 23 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 22,127 | 5,455 | |
| 2018-09-30 | 22,281 | 8,808 | 1,587 |
| 2018-06-30 | 23,197 | 9,290 | 2,208 |
| 2018-03-31 | 24,690 | 11,243 | 3,464 |
| 2017-12-31 | 26,107 | 11,898 | 4,628 |
| 2017-09-30 | 27,478 | 12,684 | 11,601 |
| 2017-06-30 | 28,466 | 14,383 | 12,213 |
| 2017-03-31 | 29,101 | 15,842 | 12,637 |
| 2016-12-31 | 30,390 | 17,047 | 13,501 |
| 2016-09-30 | 31,576 | 18,382 | 15,076 |
| 2016-06-30 | 32,371 | 18,085 | 16,346 |
| 2016-03-31 | 32,839 | 18,758 | 17,341 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 23 Analyst Estimates (S&P Global) | See Below |
All data from Gilead Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 6.60 | 10.51 | 4.62 | 5.00 |
| 2022-12-31 | 6.07 | 9.44 | 3.95 | 5.00 |
| 2021-12-31 | 6.05 | 8.14 | 4.82 | 6.00 |
| 2020-12-31 | 5.69 | 7.06 | 4.78 | 9.00 |
| 2019-12-31 | 5.10 | 5.34 | 4.74 | 12.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 4.20 |
| 2018-09-30 | 1.22 |
| 2018-06-30 | 1.69 |
| 2018-03-31 | 2.65 |
| 2017-12-31 | 3.54 |
| 2017-09-30 | 8.86 |
| 2017-06-30 | 9.30 |
| 2017-03-31 | 9.57 |
| 2016-12-31 | 10.08 |
| 2016-09-30 | 11.01 |
| 2016-06-30 | 11.65 |
| 2016-03-31 | 12.06 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Gilead Sciences is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
Future performance checks
We assess Gilead Sciences's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Gilead Sciences has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
GILD Past Performance
How has Gilead Sciences performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Gilead Sciences's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Gilead Sciences's 1-year earnings growth exceeds its 5-year average (17.9% vs -9.1%)
- Gilead Sciences's earnings growth has not exceeded the US Biotechs industry average in the past year (17.9% vs 40%).
Earnings and Revenue History
All data from Gilead Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 22,127.00 | 5,455.00 | 4,013.00 | 4,175.00 |
| 2018-09-30 | 22,281.00 | 1,587.00 | 4,129.00 | 4,218.00 |
| 2018-06-30 | 23,197.00 | 2,208.00 | 4,060.00 | 4,068.00 |
| 2018-03-31 | 24,690.00 | 3,464.00 | 3,977.00 | 3,740.00 |
| 2017-12-31 | 26,107.00 | 4,628.00 | 3,830.00 | 3,734.00 |
| 2017-09-30 | 27,478.00 | 11,601.00 | 3,618.00 | 3,591.00 |
| 2017-06-30 | 28,466.00 | 12,213.00 | 3,570.00 | 3,826.00 |
| 2017-03-31 | 29,101.00 | 12,637.00 | 3,563.00 | 4,446.00 |
| 2016-12-31 | 30,390.00 | 13,501.00 | 3,398.00 | 4,666.00 |
| 2016-09-30 | 31,576.00 | 15,076.00 | 3,472.00 | 4,416.00 |
| 2016-06-30 | 32,371.00 | 16,346.00 | 3,544.00 | 4,135.00 |
| 2016-03-31 | 32,839.00 | 17,341.00 | 3,466.00 | 3,469.00 |
| 2015-12-31 | 32,639.00 | 18,108.00 | 3,426.00 | 3,014.00 |
| 2015-09-30 | 31,447.00 | 16,912.00 | 3,236.00 | 2,952.00 |
| 2015-06-30 | 29,194.00 | 15,043.00 | 3,278.00 | 2,839.00 |
| 2015-03-31 | 27,485.00 | 14,207.00 | 3,080.00 | 2,608.00 |
| 2014-12-31 | 24,890.00 | 12,101.00 | 2,983.00 | 2,854.00 |
| 2014-09-30 | 20,696.14 | 9,405.60 | 2,560.85 | 2,408.66 |
| 2014-06-30 | 17,436.97 | 7,463.21 | 2,022.71 | 2,294.91 |
| 2014-03-31 | 13,669.37 | 4,579.81 | 1,813.70 | 2,220.39 |
| 2013-12-31 | 11,202.00 | 3,075.00 | 1,699.00 | 2,120.00 |
| 2013-09-30 | 10,585.15 | 3,045.94 | 1,538.33 | 1,952.04 |
| 2013-06-30 | 10,228.91 | 2,932.84 | 1,451.05 | 1,901.63 |
| 2013-03-31 | 9,866.70 | 2,871.80 | 1,378.57 | 1,785.39 |
| 2012-12-31 | 9,702.00 | 2,592.00 | 1,280.00 | 1,652.00 |
| 2012-09-30 | 9,314.61 | 2,494.17 | 1,314.97 | 1,622.42 |
| 2012-06-30 | 9,009.67 | 2,559.79 | 1,291.31 | 1,446.66 |
| 2012-03-31 | 8,741.74 | 2,594.45 | 1,263.08 | 1,332.82 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Whilst Gilead Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
- Gilead Sciences used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
- Gilead Sciences's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Gilead Sciences's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Gilead Sciences has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
GILD Health
How is Gilead Sciences's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Gilead Sciences's finances.
The net worth of a company is the difference between its assets and liabilities.
- Gilead Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Gilead Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Gilead Sciences Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 21,534.00 | 31,536.00 | 31,512.00 |
| 2018-09-30 | 23,007.00 | 27,317.00 | 29,765.00 |
| 2018-06-30 | 21,734.00 | 29,060.00 | 27,103.00 |
| 2018-03-31 | 20,651.00 | 29,054.00 | 24,679.00 |
| 2017-12-31 | 20,501.00 | 33,542.00 | 26,145.00 |
| 2017-09-30 | 25,254.00 | 29,262.00 | 29,070.00 |
| 2017-06-30 | 23,091.00 | 26,296.00 | 21,610.00 |
| 2017-03-31 | 20,917.00 | 26,321.00 | 14,708.00 |
| 2016-12-31 | 19,363.00 | 26,346.00 | 11,895.00 |
| 2016-09-30 | 17,360.00 | 27,071.00 | 12,266.00 |
| 2016-06-30 | 16,115.00 | 22,127.00 | 8,752.00 |
| 2016-03-31 | 14,019.00 | 22,030.00 | 8,319.00 |
| 2015-12-31 | 19,115.00 | 22,055.00 | 14,607.00 |
| 2015-09-30 | 17,948.00 | 22,225.00 | 15,714.00 |
| 2015-06-30 | 16,641.00 | 12,274.00 | 8,611.00 |
| 2015-03-31 | 17,599.00 | 12,363.00 | 14,514.00 |
| 2014-12-31 | 15,834.00 | 12,404.00 | 10,128.00 |
| 2014-09-30 | 13,890.99 | 9,410.06 | 6,316.33 |
| 2014-06-30 | 16,465.22 | 9,504.54 | 8,799.07 |
| 2014-03-31 | 13,747.96 | 9,803.77 | 6,469.03 |
| 2013-12-31 | 11,809.00 | 6,636.00 | 2,132.00 |
| 2013-09-30 | 11,192.47 | 7,313.42 | 2,090.49 |
| 2013-06-30 | 11,343.38 | 7,337.72 | 2,287.37 |
| 2013-03-31 | 10,392.47 | 7,997.56 | 1,942.78 |
| 2012-12-31 | 9,550.87 | 8,223.99 | 1,862.25 |
| 2012-09-30 | 8,750.16 | 8,771.22 | 1,695.49 |
| 2012-06-30 | 8,083.39 | 9,099.14 | 1,707.54 |
| 2012-03-31 | 7,364.08 | 9,427.25 | 1,451.94 |
- Gilead Sciences's level of debt (146.4%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (56.4% vs 146.4% today).
- Debt is well covered by operating cash flow (27.9%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 8.4x coverage).
Financial health checks
We assess Gilead Sciences's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Gilead Sciences has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
GILD Dividends
What is Gilead Sciences's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Gilead Sciences
shares you are expected to receive
$77
in your first year as a dividend.
Dividend Amount
- Gilead Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.4%).
- Gilead Sciences's dividend is above the markets top 25% of dividend payers in United States of America (3.54%).
Upcoming dividend payment
Purchase Gilead Sciences on or before the 'Buy Limit' to receive their next dividend payment.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 23 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 22 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2001 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.5% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | 3.35 | 2.00 |
| 2022-12-31 | 3.13 | 2.00 |
| 2021-12-31 | 2.85 | 4.00 |
| 2020-12-31 | 2.71 | 8.00 |
| 2019-12-31 | 2.51 | 11.00 |
| Date (Data in $) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-04 | 2.520 | 3.744 |
| 2018-10-25 | 2.280 | 3.356 |
| 2018-07-25 | 2.280 | 3.039 |
| 2018-05-01 | 2.280 | 3.224 |
| 2018-02-06 | 2.280 | 2.958 |
| 2017-10-26 | 2.080 | 2.744 |
| 2017-07-28 | 2.080 | 2.632 |
| 2017-05-02 | 2.080 | 3.063 |
| 2017-02-07 | 2.080 | 3.057 |
| 2016-11-01 | 1.880 | 2.553 |
| 2016-07-25 | 1.880 | 2.408 |
| 2016-04-28 | 1.880 | 2.211 |
| 2016-02-02 | 1.720 | 1.874 |
| 2015-10-27 | 1.720 | 1.713 |
| 2015-07-28 | 1.720 | 1.612 |
| 2015-04-30 | 1.720 | 1.518 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Whilst dividend payments have been stable, Gilead Sciences has been paying a dividend for less than 10 years.
- Dividend payments have increased, but Gilead Sciences only paid a dividend in the past 4 years.
Current Payout to shareholders
What portion of
Gilead Sciences's earnings are
paid
to the shareholders as a dividend.
- Dividends paid are covered by earnings (1.8x coverage).
- Dividends after 3 years are expected to be well covered by earnings (2.5x coverage).
Income/ dividend checks
We assess Gilead Sciences's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Gilead Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Gilead Sciences has a total score of 4/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
GILD Management
CEO
| COMPENSATION | $5,325,570 |
| AGE | 52 |
| TENURE AS CEO | 0.1 years |
CEO Bio
Mr. Gregg H. Alton has been Chief Patient Officer at Gilead Sciences, Inc., since August 14, 2018 and as its Interim Chief Executive Officer since March 1, 2019. Mr. Alton joined Gilead Sciences, Inc. nearly 20 years ago and was the architect of its access program, which has enabled Gilead’s HIV medicines to reach more than 11 million people in the developing world. Mr. Alton served as Executive Vice President, International Operations and Corporate Affairs at Gilead Sciences, Inc., since April 2018 until August 15, 2018. Mr. Alton served as an Executive Vice President of Corporate & Medical Affairs at Gilead Sciences, Inc. since August 03, 2009 and its Interim Head of International Commercial Operations since March 2018 until April 2018. Mr. Alton serves as an Executive Vice President of Corporate and Medical Affairs at Gilead Palo Alto, Inc. He served as Secretary of Gilead Sciences, Inc. Mr. Alton served as Senior Vice President of Gilead Sciences, Inc. from July 2005 to August 03, 2009 and also served as its General Counsel from 2000 to August 03, 2009. He served as Vice President at Gilead Sciences, Inc. from 2001 to July 2005 and served as its Associate General Counsel from 1999 to 2001. From 2000 to 2009, Mr. Alton served various positions with Gilead, including General Counsel, Vice President and Senior Vice President. He joined Gilead in 1999. Mr. Alton served as an Attorney at the law firm of Cooley Godward LLP, where his practice focus was mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton served as the Chairman of the Board of BayBio. He serves as a Director of Collidion Inc. He serves as a Director BayBio. He serves as a Member of the Board of AIDS Healthcare Foundation. He serves as a Member of the advisory board of BIO Ventures for Global Health. He served as a Director of Eiger BioPharmaceuticals, Inc. until March 22, 2016. He served as an Independent Director at Sonoma Pharmaceuticals, Inc. (Oculus Innovative Sciences, Inc.) from January 16, 2008 to March 1, 2013. He served as a Non-Employee Director of Celladon Corporation since August 2013. He served as a Director of Bay Area Bioscience Association. Mr. Alton is a Treasurer and Director of the Biotechnology Industry Organization's General Counsel Committee and AIDS Healthcare Foundation. Mr. Alton holds a JD from Stanford University and a BA in Legal Studies from the University of California at Berkeley.
CEO Compensation
- Gregg's compensation has been consistent with company performance over the past year.
- Gregg's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Gilead Sciences management team in years:
- The tenure for the Gilead Sciences management team is about average.
Management Team
Robin Washington
CFO & Executive VP
$6M
55
10.8 yrs
Kevin Young
Advisory
$6M
60
1.1 yrs
Gregg Alton
Interim CEO & Chief Patient Officer
$5M
52
0.1 yrs
John McHutchison
Chief Scientific Officer and Head of Research & Development
Sung Lee
VP of Investor Relations
2.7 yrs
Brett Pletcher
Executive VP
3.6 yrs
Andrew Dickinson
Executive Vice President of Corporate Development & Strategy
48
0.7 yrs
Katie Watson
Executive Vice President of Human Resources
3 yrs
Bill Lee
Executive Vice President of Research
$570K
63
18.3 yrs
Taiyin Yang
Executive Vice President of Pharmaceutical Development & Manufacturing
64
13.6 yrs
Board of Directors Tenure
Average tenure and age of the Gilead Sciences board of directors in years:
- The tenure for the Gilead Sciences board of directors is about average.
Board of Directors
John Martin
Chairman of the Board
$7M
66
2.9 yrs
Gayle Wilson
Independent Director
$431K
75
17.3 yrs
Rich Whitley
Independent Director & Member of Independent Health Policy Advisory Board
$431K
72
Per Wold-Olsen
Independent Director
$451K
71
9.1 yrs
Joel Huff
Chairperson of Scientific Advisory Board
Kelly Kramer
Director
$396K
50
2.5 yrs
John Cogan
Lead Independent Director
$456K
71
5.8 yrs
Paul Berg
Member of Scientific Advisory Board
$16K
91
George Shultz
Advisor & Director Emeritus
97
13.1 yrs
Eugene Schiff
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 21. Feb 18 | Sell | Gregg Alton | Individual | 20. Feb 18 | 20. Feb 18 | -14,435 | $81.54 | $-1,176,992 | ||
Management checks
We assess Gilead Sciences's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Gilead Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
GILD News
Simply Wall St News
What Investors Should Know About Gilead Sciences, Inc.'s (NASDAQ:GILD) Financial Strength
the health of the financials determines whether the company continues to succeed. … Today we will look at Gilead Sciences’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Note that this information is centred entirely on financial health and is a high-level overview, so I encourage you to look further
Simply Wall St - – Full articleCalculating The Fair Value Of Gilead Sciences, Inc. (NASDAQ:GILD)
by estimating the company's future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleShould You Be Worried About Insider Transactions At Gilead Sciences, Inc. (NASDAQ:GILD)?
That means that an insider was selling shares at around the current price of US$67.72. … We usually pause to reflect on the potential that a stock has a high valuation, if insiders have been selling at around the current price. … All up, insiders sold more shares in Gilead Sciences than they bought, over the last year
Simply Wall St - – Full articleDoes Gilead Sciences Inc's (NASDAQ:GILD) CEO Pay Reflect Performance?
First, this article will compare CEO compensation with compensation at other large companies. … How Does John Milligan's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Gilead Sciences Inc has a market cap of US$86b, and is paying total annual CEO compensation of US$15m.
Simply Wall St - – Full articleHow Much Of Gilead Sciences Inc (NASDAQ:GILD) Do Institutions Own?
The big shareholder groups in Gilead Sciences Inc (NASDAQ:GILD) have power over the company. … Gilead Sciences is a pretty big company. … Taking a look at the our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleA Look At The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD)
I am going to run you through how I calculated the intrinsic value of Gilead Sciences Inc (NASDAQ:GILD). … by taking the expected future cash flows and discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model
Simply Wall St - – Full articleWith An ROE Of 10.3%, Can Gilead Sciences Inc (NASDAQ:GILD) Catch Up To The Industry?
and want to learn about Return on Equity using a real-life example. … Gilead Sciences Inc’s (NASDAQ:GILD) most recent return on equity was a substandard 10.3% relative to its industry performance of 18.1% over the past year. … See our latest analysis for Gilead Sciences
Simply Wall St - – Full articleDoes Gilead Sciences Inc's (NASDAQ:GILD) CEO Salary Reflect Performance?
Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … Incentives can be in the form of compensation, which should always be structured in a way that promotes value-creation to shareholders. … CEOs leading companies of similar size and profitability
Simply Wall St - – Full articleWhat You Must Know About Gilead Sciences Inc's (NASDAQ:GILD) Major Investors
In this article, I will take a quick look at Gilead Sciences Inc’s (NASDAQ:GILD) recent ownership structure – an unconventional investing subject, but an important one. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.
Simply Wall St - – Full articleWhat Should You Know About Gilead Sciences Inc's (NASDAQ:GILD) Future?
In March 2018, Gilead Sciences Inc (NASDAQ:GILD) released its most recent earnings update. … the consensus outlook from analysts appear highly confident, … as a 90.49% rise in profits is expected in the upcoming year,
Simply Wall St - – Full articleGILD Company Info
Map
Description
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for blood cancer; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; TARGET PharmaSolutions, Inc.; Scholar Rock Holding Corporation; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Details
| Name: | Gilead Sciences, Inc. |
| GILD | |
| Exchange: | NasdaqGS |
| Founded: | 1987 |
| $85,868,360,000 | |
| 1,282,000,000 | |
| Website: | http://www.gilead.com |
| Address: |
Gilead Sciences, Inc. 333 Lakeside Drive, Foster City, California, 94404, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | GILD | Common Stock | Nasdaq Global Select | US | USD | 22. Jan 1992 | |
| DB | GIS | Common Stock | Deutsche Boerse AG | DE | EUR | 22. Jan 1992 | |
| XTRA | GIS | Common Stock | XETRA Trading Platform | DE | EUR | 22. Jan 1992 | |
| LSE | 0QYQ | Common Stock | London Stock Exchange | GB | USD | 22. Jan 1992 | |
| SWX | GILD | Common Stock | SIX Swiss Exchange | CH | CHF | 22. Jan 1992 | |
| BIT | GILD | Common Stock | Borsa Italiana | IT | EUR | 22. Jan 1992 | |
| WBAG | GILD | Common Stock | Wiener Boerse AG | AT | EUR | 22. Jan 1992 | |
| SNSE | GILD | Common Stock | Santiago Stock Exchange | CL | USD | 22. Jan 1992 | |
| BMV | GILD * | Common Stock | Bolsa Mexicana de Valores | MX | MXN | 22. Jan 1992 | |
| BOVESPA | GILD34 | BDR EACH REPR 1/2 COM USD0.001 | Bolsa de Valores de Sao Paulo | BR | BRL | 25. Apr 2016 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/21 23:38 |
| End of day share price update: | 2019/02/21 00:00 |
| Last estimates confirmation: | 2019/02/20 |
| Last earnings filing: | 2019/02/04 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
